摘要
目的观察瑞舒伐他汀和阿托伐他汀对行经皮冠状动脉介入治疗(PCI)患者的血脂影响。方法回顾性分析行PCI术的ST段抬高型急性心肌梗死(STEMI)患者的病历资料,阿托伐他汀组361例,瑞舒伐他汀组291例。阿托伐他汀组给予阿托伐他汀片20 mg,每天1次;瑞舒伐他汀组给予瑞舒伐他汀10 mg,每天一次。PCI术前和术后1个月,分别记录患者的低密度脂蛋白胆固醇(LDL-C),甘油三酯(TG),总胆固醇(TC),高密度脂蛋白胆固醇(HDL-C)等指标数值,并记录丙氨酸氨基转移酶(ALT),天冬氨酸氨基转移酶(AST),肌酸激酶(CK)等安全性指标。结果PCI术后1个月,阿托伐他汀组和瑞舒伐他汀组分别有142,146例患者达到LDL-C目标。血脂达标率分别为39.33%(142例/361例)和50.17%(146例/291例),差异有统计学意义(P<0.05)。阿托伐他汀组和瑞舒伐他汀组患者药物不良反应发生率分别为0.28%和0,差异无统计学意义(P>0.05)。结论瑞舒伐他汀在PCI术后患者中降低LDL-C疗效更佳,且2种他汀应用于PCI患者均较为安全。
Objective To compare the lipid-lowering effects of rosuvastatin and atorvastatin in patients undergoing percutaneous coronary intervention(PCI).Methods A retrospective analysis was performed patients with ST-segment elevation acute myocardial infarction(STEMI)who underwent,361 patients in atorvastatin group and 291 patients in rosuvastatin group.Atorvastatin group was treated with atorvastatin 20 mg,and rosuvastatin group was treated with rosuvastatin 10 mg,once daily.Record the patient’s low-density lipoprotein cholesterol(LDL-C),triglyceride(TG),total cholesterol(TC),and high-density lipoprotein cholesterol(HDL-C)before PCI and 1 month after PCI.Safety parameters were also recorded including alanine aminotransferase(ALT),aspartate aminotransferase(AST)and creatine kinase(CK).Results One month after PCI,there were 142,146 patients achieving LDL-C target in atorvastatin group and rosuvastatin group,respectively.And the percentage were 39.33%(142 cases/361 cases)and 50.17%(146 cases/291 cases),with significant difference(P<0.05).There was no significant difference in the incidence of adverse drug reactions between the atorvastatin group and rosuvastatin group(0.28%vs 0).Conclusion Rosuvastatin is more effective in reducing LDL-C in patients after PCI,and the two statins were safe for patients underwent PCI.
作者
张芸楠
穆煜
林阳
石秀锦
仇琪
ZHANG Yun-nan;MU Yu;LIN Yang;SHI Xiu-jin;QIU Qi(Department of Pharmacy,Beijing Anzhen Hospital,Capital Medicine University,Beijing 100029,China;School of Pharmaceutical Sciences,Capital Medical University,Beijing 100069,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2020年第17期2614-2616,共3页
The Chinese Journal of Clinical Pharmacology
基金
科技部十三五“新药创制”重大专项基金资助项目(2017ZX09304017)
北京市医院管理局“扬帆计划”基金资助项目(ZYLX2018051)。
